168 related articles for article (PubMed ID: 31345736)
1. FDA approval of GLP-1 receptor agonist (liraglutide) for use in children.
Bacha F
Lancet Child Adolesc Health; 2019 Sep; 3(9):595-597. PubMed ID: 31345736
[No Abstract] [Full Text] [Related]
2. Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial.
Athyros VG; Katsiki N; Tentolouris N
Curr Vasc Pharmacol; 2016; 14(5):469-473. PubMed ID: 27633290
[No Abstract] [Full Text] [Related]
3. Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population.
Nguyen H; Dufour R; Caldwell-Tarr A
Adv Ther; 2017 Mar; 34(3):658-673. PubMed ID: 28078541
[TBL] [Abstract][Full Text] [Related]
4. Liraglutide.
Drucker DJ; Dritselis A; Kirkpatrick P
Nat Rev Drug Discov; 2010 Apr; 9(4):267-8. PubMed ID: 20357801
[TBL] [Abstract][Full Text] [Related]
5. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists.
Edelman SV
J Fam Pract; 2017 Oct; 66(10 Suppl):S12-S16. PubMed ID: 28991932
[TBL] [Abstract][Full Text] [Related]
6. Liraglutide for Type 2 diabetes and obesity: a 2015 update.
Iepsen EW; Torekov SS; Holst JJ
Expert Rev Cardiovasc Ther; 2015; 13(7):753-67. PubMed ID: 26106933
[TBL] [Abstract][Full Text] [Related]
7. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Using Combinations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist.
Baron HL
J Fam Pract; 2017 Oct; 66(10 Suppl):S17-S28. PubMed ID: 28991933
[TBL] [Abstract][Full Text] [Related]
8. [Effects of GLP-1 receptor agonists on carbohydrate metabolism control].
Fernández-García JC; Colomo N; Tinahones FJ
Med Clin (Barc); 2014; 143 Suppl 2():18-22. PubMed ID: 25326839
[TBL] [Abstract][Full Text] [Related]
9. Maturity-Onset diabetes of the young type 5 treated with the glucagon-like peptide-1 receptor agonist: A case report.
Terakawa A; Chujo D; Yasuda K; Ueno K; Nakamura T; Hamano S; Ohsugi M; Tanabe A; Ueki K; Kajio H
Medicine (Baltimore); 2020 Aug; 99(35):e21939. PubMed ID: 32871938
[TBL] [Abstract][Full Text] [Related]
10. Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations.
Blumer I; Pettus JH; Santos Cavaiola T
Postgrad Med; 2018 May; 130(4):375-380. PubMed ID: 29521173
[TBL] [Abstract][Full Text] [Related]
11. Update: Pediatric Diabetes.
Gujral J; Sethuram S; Rapaport R
J Diabetes; 2020 Mar; 12(3):262-264. PubMed ID: 31837125
[No Abstract] [Full Text] [Related]
12. Use of GLP-1 RAs in Cardiovascular Disease Prevention: A Practical Guide.
Lingvay I; Leiter LA
Circulation; 2018 May; 137(21):2200-2202. PubMed ID: 29784677
[No Abstract] [Full Text] [Related]
13. Drug Combo Adds No Benefit in Patients with Type 2 Diabetes.
Geurin MD
Am Fam Physician; 2016 Mar; 93(6):436-8. PubMed ID: 26977827
[No Abstract] [Full Text] [Related]
14. Newer classes of antidiabetes drugs: ophthalmological considerations for GLP-1R agonists, DPP-4 inhibitors, and SGLT-2 inhibitors.
McReelis KD; Lovshin JA
Can J Ophthalmol; 2017 Nov; 52 Suppl 1():S4-S7. PubMed ID: 29074013
[No Abstract] [Full Text] [Related]
15. [SGLT2 inhibitor or GLP-1 receptor agonist in a patient with type 2 diabetes and cardiovascular disease ?].
Scheen AJ; Paquot N
Rev Med Liege; 2018 Jan; 73(1):43-50. PubMed ID: 29388411
[TBL] [Abstract][Full Text] [Related]
16. Diabetic nephropathy: Renoprotective effects of GLP1R agonists and SGLT2 inhibitors.
Hocher B; Tsuprykov O
Nat Rev Nephrol; 2017 Dec; 13(12):728-730. PubMed ID: 28989173
[No Abstract] [Full Text] [Related]
17. Role of glucagon-like peptide 1 receptor agonists in management of obesity.
Isaacs D; Prasad-Reddy L; Srivastava SB
Am J Health Syst Pharm; 2016 Oct; 73(19):1493-507. PubMed ID: 27521241
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-like peptide-1 receptor agonist prescribing patterns in adolescents with type 2 diabetes.
Bensignor MO; Wolf JM; Rudser KD; Kelly AS; Arslanian S
Diabetes Obes Metab; 2022 Jul; 24(7):1380-1384. PubMed ID: 35491535
[No Abstract] [Full Text] [Related]
19. Does Neprilysin Inhibition Potentiate or Minimize the Adverse Effects of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Heart Failure?
Packer M
J Card Fail; 2018 Feb; 24(2):109-111. PubMed ID: 29305970
[No Abstract] [Full Text] [Related]
20. Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.
Smits MM; Tonneijck L; Muskiet MH; Kramer MH; Pouwels PJ; Pieters-van den Bos IC; Hoekstra T; Diamant M; van Raalte DH; Cahen DL
Diabetologia; 2016 Dec; 59(12):2588-2593. PubMed ID: 27627981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
